Case Study: Chronic Candida and Metabolic Syndrome in a 45-Year-Old Man — Yeast Eradication, Blood Sugar Stabilisation, and Weight Loss Using the Functional Health Matrix

Educational composite — not a single patient. This case study is an illustrative composite of a 45-year-old man with chronic candida overgrowth and metabolic syndrome — insulin resistance, central weight gain, and a history of antibiotic-driven gut mycobiome disruption. It shows how a structured antifungal protocol, blood-sugar stabilisation, and gut mycobiome restoration can break the candida–hyperglycaemia loop when implemented carefully in collaboration with a registered clinician. It does not describe one identifiable patient; names, demographic specifics, and quoted dialogue are constructed for educational illustration. Always work with a registered clinician for individual care. Editorial review by Chris Massamba, Dip CNM, FMCHC.

Key learning points

• Antibiotic-induced gut mycobiome disruption can drive a self-reinforcing loop: candida overgrowth raises blood glucose, and hyperglycaemia feeds further yeast proliferation.
• Metabolic syndrome may be downstream of gut fungal dysbiosis rather than an independent condition. Treating insulin resistance without assessing the mycobiome risks treating symptoms alone.
• Oral thrush in a non-immunocompromised adult is a visible marker of systemic candida burden and warrants investigation of the gut mycobiome and glycaemic status.
• Saccharomyces boulardii directly antagonises Candida albicans by inhibiting the yeast-to-hyphal transition and supporting secretory IgA production.
• Outcomes are illustrative and reflect composite patterns. Individual responses vary depending on genetics, adherence, co-morbidities, and practitioner oversight.

Patient Presentation

David (not his real name), a 45-year-old IT project manager from Manchester, presented in February 2026 with a four-year constellation of symptoms managed piecemeal in primary care. In his words: "I've been told I've got metabolic syndrome but no one's explained why a fit-ish 45-year-old has the blood work of a 65-year-old. I've put on two stone in three years, mostly around my belly. I'm exhausted by 3 p.m. My sugar cravings are uncontrollable. And I've had this white coating on my tongue for months — the GP gave me fluconazole twice, it cleared for a fortnight then came straight back. No one's asked what I'm eating or what's going on in my gut."

The timeline showed a cascade. In 2019 he completed two consecutive courses of broad-spectrum antibiotics (clarithromycin, then co-amoxiclav) for a persistent chest infection. Within weeks of the second course he developed bloating, near-compulsive sugar cravings, and his first oral thrush. Over eighteen months his weight climbed from 82 kg to 94 kg, waist circumference reached 108 cm, and an NHS health check showed fasting glucose 6.7 mmol/L, triglycerides 2.9 mmol/L, and HDL 0.9 mmol/L — three of the five NCEP ATP III criteria for metabolic syndrome — with blood pressure of 148/92 mmHg.

He also reported fungal nail infections on both great toes (two years, unresponsive to topical terbinafine), perianal itching, and "fuzzy thinking." He worked 55-hour weeks, ate desk-bound supermarket meal deals, drank four to five pints of lager on two evenings weekly, and used sugary snacks to bridge afternoon energy crashes. Metformin 500 mg twice daily, prescribed eighteen months earlier, had been discontinued after six weeks for gastrointestinal side effects.

Initial Clinical Assessment

A structured symptom review by body system — informed by the Stewart Nutrition practitioner reference (Stewart, 2016) and aligned with NICE Clinical Knowledge Summaries and NIH Office of Dietary Supplements guidance — mapped David's presentation against likely nutritional and metabolic drivers. Red flags were excluded: no immunocompromise, no steroid use, no malignancy, and glucose in the prediabetic (not diabetic) range.

Legend: Illustrative composite, not a single patient; details constructed for education.

Interpretation: The picture cohered as a self-reinforcing loop. Antibiotic-induced dysbiosis permitted Candida albicans overgrowth, driving intestinal permeability, low-grade inflammation, and progressive insulin resistance (Li et al., 2023); the resulting hyperglycaemia created a glucose-rich mucosa that further favoured yeast. The metabolic-syndrome diagnosis was downstream of the mycobiome disturbance, not independent of it.

From the literature: "The gut mycobiome plays an important role in maintaining intestinal homeostasis and its dysbiosis can contribute to the development of metabolic diseases including obesity, type 2 diabetes, and non-alcoholic fatty liver disease." -- Li et al., Biomed Pharmacother 2023

Functional Health Matrix Assessment

David was scored across all seven nodes of the Functional Health Matrix, with 1 representing severe dysfunction and 5 representing optimal function:

Total Initial Matrix Score: 12/35 — moderate-to-severe dysfunction. The FHM is a clinical-reasoning framework, not a validated test; its value here was sequencing, not scoring.

Interpretation: Three nodes sat at crisis level (1/5): Assimilation (fungal overgrowth and gut permeability), Communication (insulin signalling), and Energy Production (mitochondrial substrate delivery). Assimilation was the origin and insulin resistance the amplifier — a self-reinforcing loop that single-agent fluconazole could not break. This triad distinguishes metabolic syndrome with fungal dysbiosis from that driven by dietary excess alone.

Wheel of Life Assessment

Total Initial Wheel of Life Score: 31/80 — pronounced imbalance across the physical-health domains. Scores are self-reported with practitioner clarification.

Interpretation: Nutrition (2/10) and Stress Management (2/10) were the most collapsed dimensions and also the two most directly tied to the candida-hyperglycaemia loop: a sugar-rich diet fed the yeast, while chronic work stress sustained cortisol-driven glucose mobilisation. We therefore prioritised diet and stress before intense exercise. Preserved Purpose (6/10) and Relationships (5/10) provided motivational anchors for change.

Functional Testing Ordered

Based on the clinical presentation and matrix assessment, the following functional investigations were ordered. For a broader discussion of functional medicine lab rationale, see the companion reference article.

GI-MAP Comprehensive Stool Analysis (Diagnostic Solutions Laboratory):

• Candida albicans: 3.8 x 10^3 (elevated; reference <1.0 x 10^3)
• Candida spp.: 4.2 x 10^3 (elevated; reference <1.0 x 10^3)
• Faecal zonulin: 158 ng/mL (elevated; reference <107 ng/mL) — indicating increased intestinal permeability
• Faecal secretory IgA: 412 microg/g (low-normal; reference 500-2,040 microg/g) — suggesting mucosal immune depression
• Bacteroidetes/Firmicutes ratio: markedly shifted towards Firmicutes with reduced diversity — dysbiosis pattern associated with obesity and insulin resistance (Li et al., 2023)
• Elastase-1: 310 microg/g (adequate; reference >200 microg/g) — pancreatic exocrine function preserved
• beta-glucuronidase: elevated at 5,280 U/g (reference <3,600 U/g) — impaired Phase II detoxification and oestrogen recirculation

Comprehensive Metabolic Panel (fasting):

• Fasting glucose: 6.7 mmol/L (impaired; optimal <5.6 mmol/L)
• HbA1c: 44 mmol/mol / 6.2% (prediabetic range; optimal <37 mmol/mol)
• Fasting insulin: 18.2 microIU/mL (elevated; optimal <8 microIU/mL)
• HOMA-IR: 4.8 (severe insulin resistance; optimal <1.7)
• Triglycerides: 2.9 mmol/L (elevated; optimal <1.7 mmol/L)
• HDL cholesterol: 0.9 mmol/L (low; optimal >1.0 mmol/L for men)
• ALT: 52 U/L (mildly elevated; optimal <35 U/L)
• hs-CRP: 4.8 mg/L (elevated; optimal <1.0 mg/L)
• Uric acid: 428 micromol/L (high-normal; optimal <360 micromol/L)

Nutritional Assessment:

• Serum magnesium (RBC): 1.58 mmol/L (low; optimal 1.8-2.5 mmol/L)
• Serum zinc: 11.2 micromol/L (low-normal; optimal 13-18 micromol/L)
• Vitamin D (25-OH): 42 nmol/L (insufficient; optimal 100-150 nmol/L — NICE reference >50 nmol/L for adequacy but this is a bone-centric threshold) (Holick et al., 2011). For obesity-adjusted vitamin D dosing considerations, see the related guidance.
• Serum B12: 268 pg/mL (low-normal; optimal >500 pg/mL per functional medicine ranges)
• Serum ferritin: 89 microg/L (adequate; optimal 100-150 microg/L with hs-CRP context — likely depressed by inflammatory block)

Urinary Organic Acids (Great Plains Laboratory — OAT):

• D-Arabinitol: 72 mmol/mol creatinine (elevated; reference <29) — a fungal metabolite confirming significant intestinal yeast overgrowth (Li et al., 2023)
• Tartaric acid: 86 mmol/mol creatinine (elevated; reference <22) — further yeast marker
• Citramalic acid: elevated — yeast/clostridial marker

Testing confirmed the hypothesis: intestinal Candida overgrowth with elevated fungal metabolites (Li et al., 2023), increased permeability (zonulin), depressed mucosal immunity (low sIgA), severe insulin resistance (HOMA-IR 4.8), and nutritional deficiencies (Stewart, 2016). Optimal ranges are labelled as practitioner preference, not guideline thresholds. The raised beta-glucuronidase flagged impaired detoxification to address in Phase 2.

Intervention Protocol

The protocol was structured across three phases, sequenced to avoid overwhelming David's detoxification capacity whilst addressing the root drivers systematically.

Phase 1: Remove and Stabilise (Weeks 1-4)

Diet — anti-candida, low-glycaemic-load. Complete elimination of refined sugars, syrups, artificial sweeteners, high-glycaemic carbohydrates, and alcohol (a yeast substrate and acetaldehyde burden); fermented foods paused during early die-off. A whole-foods pattern of non-starchy vegetables, adequate protein (1.2 g/kg, ~110 g daily), and healthy fats, with daily cruciferous vegetables for hepatic sulphation. The diet served three ends at once: starving yeast of glucose, blunting post-prandial insulin, and restoring nutrient density. This mirrors the Remove phase of the 5R gut health protocol.

Supplements below are adjuncts to the dietary and lifestyle change, introduced under clinical supervision.

Caution — antifungal die-off. Starting antifungals at full dose risks severe Herxheimer-type reactions. Begin low and escalate over 7-10 days. Activated charcoal (1,000 mg at bedtime, 2 hours from all supplements) binds toxins during the die-off window.

Die-off management (from Day 3). David had moderate Herxheimer symptoms (headache, fatigue, joint aching) on Days 3-7, managed with hydration (3 L daily), Epsom-salt baths, a temporary drop in caprylic acid to 500 mg once daily for three days, and activated charcoal from Day 5.

Phase 2: Repair and Replenish (Weeks 5-8)

With die-off symptoms resolved by the end of Week 3 and David reporting notably reduced sugar cravings ("I walked past the biscuit aisle and didn't even notice them — that's never happened"), Phase 2 escalated the antifungal protocol and introduced microbiome restoration.

From the literature: "The antagonistic effect of Saccharomyces boulardii on Candida albicans filamentation, adhesion and biofilm formation suggests its potential as a biotherapeutic agent against candidiasis." -- Krasowska et al., FEMS Yeast Res 2009

Phase 3: Rebalance and Integrate (Weeks 9-12)

Phase 3 shifted the emphasis from active treatment to sustainable integration and metabolic resilience.

Dietary Reintroduction and Metabolic Flexibility: Gradual reintroduction of low-glycaemic fruits, legumes, and gluten-free whole grains in small portions, monitoring for symptom recurrence; fermented foods cautiously reintroduced. Continued avoidance of refined sugar, alcohol, and ultra-processed foods. A 12-hour overnight fasting window (dinner by 7 p.m., breakfast at 7 a.m.) supported circadian insulin sensitivity (Colberg et al., 2016) and overnight gut repair (Wang et al., 2015). CGM data can add clinical value by revealing individual responses to reintroduced foods.

Movement as insulin sensitiser. Daily walking 8,000-10,000 steps, including one 20-minute brisk walk after the largest meal, plus two weekly resistance sessions (bodyweight progressing to bands by Week 11). This exploits both AMPK-dependent and GLUT4-translocation pathways for glucose uptake, independent of insulin signalling — post-prandial walking is among the most potent non-pharmacological tools for glucose disposal (Colberg et al., 2016).

Stress modulation. Morning box breathing before screens; a 10-minute evening body-scan framed as "focus training" to suit David's mindset; continued alcohol abstinence; and a 9 p.m. screen curfew replaced with reading.

Maintenance. Saccharomyces boulardii 5 billion CFU daily, multi-strain probiotic 15 billion CFU daily, and caprylic acid reduced to 500 mg once daily, to be reviewed at follow-up.

Figure: David -- phased intervention timeline. Three phases across 12 weeks: Phase 1 (weeks 1-4) anti-candida diet, blood-sugar stabilisation, gentle antifungals and gut-barrier support, with a Days 3-7 die-off window; Phase 2 (weeks 5-8) escalated antifungals, microbiome restoration, hepatic and nutritional support; Phase 3 (weeks 9-12) dietary reintroduction, exercise, stress modulation, and maintenance dosing. Re-testing at week 12.

Interpretation: Deliberate sequencing pre-empted die-off overwhelm — gentle antifungals first, escalation once tolerated, hepatic support before full-dose antimicrobials — while blood-sugar stabilisation ran in parallel to break the glucose-yeast loop.

Evidence tier summary

Legend: "Strong" = systematic reviews or multiple large RCTs; "Moderate" = individual RCTs, cohort studies, or strong mechanistic data with clinical support; "Emerging" = pilot/mechanistic evidence pending further trials. Berberine has the strongest base here; S. boulardii and chromium are moderate; caprylic acid remains mechanistic.

Safety note: Patients with fasting glucose above 7.0 mmol/L or HbA1c above 48 mmol/mol (6.5%) meet diagnostic criteria for type 2 diabetes and require medical referral alongside any nutritional intervention. Never delay pharmacological management of established diabetes for a dietary protocol. David's values (6.7 mmol/L, 44 mmol/mol) fell in the prediabetic range, permitting a lifestyle-first approach.

Outcomes at 12 Weeks

David returned for his 12-week outcomes consultation in May 2026. The changes were measurable across every assessment domain and visible in his presentation — he walked into the clinic upright, engaged, and noticeably leaner.

These outcomes reflect a composite pattern. Individual responses vary depending on the severity of fungal overgrowth, metabolic status, adherence, and co-existing conditions.

Anthropometric and Metabolic Changes:

Legend: All metabolic parameters measured fasting. Changes reflect the combined effect of antifungal treatment, dietary modification, blood sugar stabilisation supplementation, and exercise prescription. Optimal ranges shown in the Functional Testing section above.

Interpretation: The HOMA-IR fall from 4.8 to 1.7 is the headline result — a shift from severe insulin resistance to the upper threshold of insulin sensitivity, achieved with lifestyle change and adjunctive supplements rather than pharmacotherapy (Hua et al., 2012; Jacob et al., 1999; Lan et al., 2015). Combined with normalised triglycerides and improved HDL, David no longer met the metabolic-syndrome criteria at 12 weeks — best framed as remission, not permanent cure. The hs-CRP fall (4.8 to 1.9) reflects reduced systemic inflammation with room for further gain at follow-up.

From the literature: "Berberine improves insulin sensitivity by multiple mechanisms including AMPK activation, reduced hepatic gluconeogenesis, and direct effects on intestinal microbiota composition." -- Lan et al., J Ethnopharmacol 2015

Repeat Functional Testing:

• GI-MAP: Candida albicans reduced to 0.8 x 10^3 (below reference threshold); Candida spp. at 0.6 x 10^3
• Faecal zonulin: reduced to 112 ng/mL (approaching the normal reference of <107 ng/mL) — indicating significant restoration of intestinal barrier integrity
• Secretory IgA: increased to 682 microg/g — mucosal immune function restored to normal range
• beta-glucuronidase: reduced to 2,940 U/g (within normal range)
• D-Arabinitol: reduced to 18 mmol/mol creatinine (below reference threshold of 29)
• Serum magnesium (RBC): 1.92 mmol/L (within optimal range)
• Vitamin D (25-OH): 108 nmol/L (within optimal range) (Holick et al., 2011)
• Serum B12: 482 pg/mL (improved substantially with methylated B12 supplementation and gut healing)

Functional Health Matrix Re-Score:

Total Final Matrix Score: 26/35 (12→26 of 35; +14 points)

Figure: Functional Health Matrix -- baseline vs 12-week follow-up (12→26 of 35; +14 points). Nodes shifting from 1-2 to 4-5 indicate successful therapeutic targeting. The greatest gains were Assimilation and Energy Production (both +3) — consistent with reduced fungal burden and restored mitochondrial efficiency — plus Biotransformation (+2) as the liver was unburdened of alcohol and yeast metabolites. Communication (+2) improved but remains the node needing longest-term vigilance given David's predisposition to metabolic syndrome.

Wheel of Life Re-Score:

Total Final Wheel of Life Score: 53/80 (31→53 of 80; +22 points)

Figure: Wheel of Life -- baseline vs 12-week follow-up (31→53 of 80; +22 points). Dimensions shifting from 1-3 to 6-8 indicate lifestyle rebalancing alongside clinical care. Nutrition (+6) was the standout; Movement (+4) and Stress Management (+4) reflected restored energy feeding back into capacity and resilience; Spiritual Practice (+1) the most modest, given an early mindfulness practice.

The most pronounced shifts were in Nutrition (+6 points) and Movement (+4 points) — domains that had been profoundly impaired and where David's commitment to the protocol produced rapid, tangible results that reinforced adherence. Sleep improved as nocturnal hypoglycaemia resolved and the evening screen curfew consolidated his circadian rhythm. Stress Management improved modestly but genuinely — David reported that the morning breathing practice had begun to feel "as automatic as brushing my teeth."

Patient Testimonial: "I didn't really believe any of this at the start, to be honest. I'm an IT guy — I like things that are measurable, and nobody had measured anything on me before except my blood sugar. But when you showed me the stool test — that there was literally too much yeast in my gut — and then explained how that was driving the insulin problem, it clicked. Three months later, I've lost over a stone and a half, I don't crave sugar at all, my head is clearer than it's been in years, and my GP has said I don't need metformin. That white coating on my tongue? Gone. The interesting bit — and I didn't expect this — is that I don't actually miss the beer. I thought that would be the hardest part, but once the cravings disappeared, it just wasn't an issue."

Medication safety — deprescribing is prescriber-led. David had already discontinued metformin (for GI intolerance) before this programme. Any decision to remain off it, or to adjust glucose-lowering therapy as glycaemia improves, rests with the prescribing clinician — made proactively, before markers fall, to pre-empt hypoglycaemia. Patients must not self-deprescribe on the strength of improving numbers.

Maintenance Plan: David was transitioned to a maintenance protocol: continued whole-foods low-glycaemic-load diet with the 12-hour overnight fast, twice-weekly resistance training and daily walking, Saccharomyces boulardii 5 billion CFU daily, multi-strain probiotic 15 billion CFU daily, magnesium glycinate 200 mg daily, omega-3 fatty acids 2 g daily, and vitamin D3 2,000 IU daily (maintenance dose post-repletion). Caprylic acid was discontinued, with a repeat GI-MAP at 24 weeks to confirm sustained mycobiome balance. He was advised to limit alcohol to occasional moderate intake and to take antibiotics, if needed, with concurrent S. boulardii and probiotic support. A 6-month follow-up was scheduled for November 2026.

Clinical Pearls

1. The gut mycobiome behaves as a metabolic organ. Fungal dysbiosis here was not a local GI nuisance but a systemic metabolic contributor: Candida albicans overgrowth can promote insulin resistance through metabolite-mediated inflammatory cascades (Li et al., 2023). Assessing the mycobiome alongside standard metabolic markers makes for more complete root-cause reasoning.
2. Address the ecosystem, not the organism alone. Two courses of fluconazole had cleared yeast transiently without altering what permitted overgrowth — the high-sugar diet, depleted microbiome, compromised barrier, and glucose-rich mucosa. Antifungal medicines have a clear place; for chronic, non-invasive candidiasis in an immunocompetent host the 5R framework tends to be more durable. Supplements here were adjuncts to diet, movement, and clinical oversight, not substitutes.
3. The oral cavity can flag the gut. Persistent oral thrush in a non-immunocompromised, non-steroid-using adult warrants investigation of the gut mycobiome and glycaemic status rather than repeated topical or single-agent treatment.
4. Deprescribe proactively, never reactively. As glycaemia improved, any glucose-lowering medication should be reviewed by the prescribing clinician before markers fall, to pre-empt hypoglycaemia. Patients must not self-deprescribe; medication changes are made by the prescriber.
5. The Functional Health Matrix is a reasoning aid, not a validated test. Its value here was sequencing — naming Assimilation as the root and insulin signalling as the amplifier — not a scored diagnosis. Individual responses vary with genetics, adherence, and co-morbidities.

Internal navigation

If this case study resonated, you may find these posts clinically relevant. If you are experiencing a medical emergency call 999; for urgent but non-emergency concerns contact NHS 111; if you are in emotional distress contact the Samaritans on 116 123 or text SHOUT to 85258.

• The 5R Gut Health Protocol: a functional medicine framework for 2026 -- the Remove-Replace-Reinoculate-Repair-Rebalance framework underpinning this protocol.
• 5R Gut Protocol 2026 Update: microbiome reinoculation and beyond -- the reinoculation phase, including Saccharomyces boulardii.
• Case Study: Chronic Fatigue, IBS, and Brain Fog -- another composite where gut dysbiosis drove systemic symptoms.
• Essential Functional Medicine Labs for 2026 -- the testing logic behind GI-MAP, organic acids, and metabolic panels.
• CGM in Functional Practice: when continuous glucose monitoring adds clinical value -- for patients whose glycaemic variability warrants monitoring.

Find an EPINUTRI practitioner